NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)
First-line treatment of advanced malignant pleural mesothelioma (MPM) is based on six cycles
of a pemetrexed-based chemotherapy, with a median progression-free survival (PFS) of
approximately 6 months.However, the median time from completion of first-line treatment to
initiation of second-line therapy is approximately 3 months. Recent experiences in non-small
cell lung cancer patients have shown that a maintenance treatment given immediately after
first-line treatment regimens can improve PFS and survival. Considering the toxicity profile
of NGR-hTNF characterized by mild-to-moderate constitutional symptoms registered in a phase
II trial in previously treated MPM patients, as well as the disease control observed in
about half of the patients and maintained for more than four months and more than nine
months in the triweekly and weekly cohorts, respectively, seems justified to compare in a
randomized phase II trial the time-related efficacy of NGR-hTNF against placebo in advanced
MPM patients who did not progress after six cycles of a standard pemetrexed-based treatment.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Progression-Free Survival (PFS)
Defined as the time from the date of randomization until disease progression, or death
every 6 weeks
No
Antonio Lambiase, MD
Study Director
MolMed S.p.A.
Italy: Ethics Committee
NGR019
NCT01358084
March 2011
June 2013
Name | Location |
---|